Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicenter retrospective study

Elisa Gremese, Andreina Manfredi, Giulia Cassone, Federica Furini, Vincenzo Venerito, Fabiola Atzeni, Eugenio Arrigoni, Giovanni Della Casa, Stefania Cerri, Marcello Govoni, Luca Petricca, Florenzo Iannone, Carlo Salvarani, Marco Sebastiani

Risultato della ricerca: Contributo in rivistaArticolo in rivista

13 Citazioni (Scopus)

Abstract

BACKGROUND: Interstitial lung disease (ILD) is the most severe extra-articular manifestation of rheumatoid arthritis (RA). Although it is responsible of 10-20% of all RA mortality, no controlled studies are available for the treatment of RA-ILD and its therapeutic approach is still debated. AIMS: In this study, we analysed the evolution of ILD in a population of RA patients treated with tocilizumab (TCZ). METHODS: In this national multicenter study, we retrospectively collected patients with RA-ILD treated with at least one dose of TCZ. For each patient, disease activity and serological data were evaluated. Moreover, we analysed the evolution of high-resolution computed tomography (HRCT) and pulmonary function tests, including forced vital capacity (FVC) and diffusing capacity of carbon monoxide (DLCO). RESULTS: Twenty-eight RA-ILD patients were identified (females/males 18/10, mean age 61.6 years), with a mean follow-up for TCZ therapy of 30 months. At the end of follow-up, FVC remained stable in 14 patients (56%), improved in 5 (20%) and worsened in 6 (24%). DLCO remained stable in 14 patients (56%), improved in 5 (20%) and worsened in 6 (24%), even though in 3 patients DLCO and FVC showed an opposite trend. HRCT remained stable in the majority of cases (25), worsened in 2 patients with a usual interstitial pneumonia pattern, improved in only one case with a nonspecific interstitial pneumonia pattern. CONCLUSIONS: The management of RA-ILD patients remains a critical unmet need. TCZ demonstrated a good safety profile in patients with RA-ILD and a potential effect on the stabilization of the lung involvement.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaInternal Medicine Journal
DOI
Stato di pubblicazionePubblicato - 2019

Keywords

  • DMARDs
  • interstitial lung disease
  • rheumatoid arthritis
  • therapy
  • tocilizumab

Fingerprint Entra nei temi di ricerca di 'Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicenter retrospective study'. Insieme formano una fingerprint unica.

Cita questo